Who are Axert's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Relpax, Frova, Amerge, Maxalt, Zomig, Imitrex.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/almotriptan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Axert — Competitive Intelligence Brief

Axert (ALMOTRIPTAN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin-1b and Serotonin-1d Receptor Agonist. Area: Neuroscience.

marketed Serotonin-1b and Serotonin-1d Receptor Agonist 5-hydroxytryptamine receptor 1B Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Axert (ALMOTRIPTAN) — Johnson & Johnson. Axert works by binding to serotonin receptors in the brain to relieve migraine pain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Axert TARGET	ALMOTRIPTAN	Johnson & Johnson	marketed	Serotonin-1b and Serotonin-1d Receptor Agonist	5-hydroxytryptamine receptor 1B	2001-01-01
Relpax	ELETRIPTAN	Upjohn	marketed	Serotonin-1b and Serotonin-1d Receptor Agonist	5-hydroxytryptamine receptor 1D	2002-01-01
Frova	FROVATRIPTAN	Endo Operations	marketed	Serotonin-1b and Serotonin-1d Receptor Agonist	5-hydroxytryptamine receptor 1D	2001-01-01
Amerge	NARATRIPTAN	GSK	marketed	Serotonin-1b and Serotonin-1d Receptor Agonist	5-HT 1B/1D receptors	1998-01-01
Maxalt	RIZATRIPTAN	Gensco	marketed	Serotonin-1b and Serotonin-1d Receptor Agonist	5-hydroxytryptamine receptor 1D	1998-01-01
Zomig	ZOLMITRIPTAN	AstraZeneca	marketed	Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]	5-hydroxytryptamine receptor 1D	1997-01-01
Imitrex	SUMATRIPTAN	GSK	marketed	Serotonin-1b and Serotonin-1d Receptor Agonist	5-hydroxytryptamine receptor 1D	1992-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2030-06-16 — Imitrex · 9974770 · Formulation · US
2030-06-16 — Imitrex · 11337962 · Formulation · US
2030-06-16 — Imitrex · 10603305 · Formulation · US
2030-06-16 — Imitrex · 9610280 · Formulation · US
2030-06-16 — Imitrex · 12090139 · Formulation · US
2031-07-19 — Imitrex · 9211282 · Formulation · US

Sponsor landscape (Serotonin-1b and Serotonin-1d Receptor Agonist class)

GSK · 2 drugs in this class
Endo Operations · 1 drug in this class
Gensco · 1 drug in this class
Johnson & Johnson · 1 drug in this class
Upjohn · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Axert — Competitive Intelligence Brief. https://druglandscape.com/ci/almotriptan. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab